A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease

Completed · Phase 3

Conditions studied: HIV Infections, AIDS-Associated Nephropathy

In brief

The purpose of this study is to compare the safety and effectiveness of saquinavir SGC plus stavudine (d4T) plus lamivudine (3TC) with that of saquinavir SGC plus nelfinavir plus d4T in patients with HIV-associated kidney disease. This study examines whether these drug combinations are effective in preventing kidney disease from progressing to a stage where it is immediately life threatening. This study also examines the effect these drug combinations have on the level of HIV detected in these patients. Finally, this study evaluates the drug level (the amount of drug found in the body) of these two combinations in patients with kidney disease.

Key facts

Study ID

NCT00002397

Run by

Hoffmann-La Roche

People needed

24

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have:
• Detectable HIV-1 RNA by Amplicor assay.
• Biopsy-proven nephropathy.

You may not qualify if…

• Prior Medication:
• Excluded:
• Saquinavir and nelfinavir.
• d4T or 3TC within the past 4 months.
• Required:
• Stable antiretroviral therapy for more than 4 weeks.

Where it is running

• Mount Sinai Med Ctr — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.